Home›Trial›NCT03333343
🔬NCT03333343Phase 1ACTIVE NOT RECRUITING

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Study Summary

The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced Epidermal growth factor receptor- mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).

Conditions
EGFR-mutant Non-small Cell Lung Cancer
Interventions / Drugs
EGF816trametinibribociclibLXH254INC280gefitinib
View on ClinicalTrials.gov ↗
Sponsor
NVS
Novartis AG
Diversified Pharma
D36/100
Study Details
Enrollment105 participants
Primary Completion—
Lead SponsorNovartis Pharmaceuticals
Data Retrieved2026-04-11 02:55:49.151844+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.